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Dear Sir:
The incidence of cerebral venous thrombosis (CVT) is on the rise, 
partly due to an improvement in the diagnostic techniques.1 
However, the therapeutic options have not changed much in the 
past three decades. Heparin followed by vitamin K antagonist 
(VKA), Warfarin is still the mainstay of treatment,2-4 although 
the limitations of VKA therapy including risk of major bleeding, 
need for constant monitoring, and drug and dietary interactions 
are all well recognized.5,6
New direct oral anticoagulants (NOACs), which are target spe-
cific for factor Xa (rivaroxaban, apixaban, edoxaban) or thrombin 
(dabigatran), were developed to overcome some of these limita-
tions. These drugs have already shown to be safer then VKA for 
recurrent venous thromboembolism and embolism prevention in 
atrial fibrillation, with fewer intracranial and extracranial hemor-
rhages, fewer fatal hemorrhages and no increase in the risk of 
gastrointestinal hemorrhages.7 Based on this safety data, and the 
efficacy results from venous thromboembolism studies, there is a 
growing tendency for neurologists to consider them for treat-
ment of CVT. A few case series have been published supporting 
the safety and efficacy of these drugs in CVT cases.8-11 More re-
cently, the results of one randomized controlled trial (randomized 
controlled trial of the safety and efficacy of dabigatran etexilate 
vs. dose-adjusted warfarin in patients with cerebral venous 
thrombosis [RESPECT CVT]) were presented at World Stroke Con-
gress in 2018.12 The trial randomized 120 patients to either dabi-
gatran or warfarin and showed no recurrence of venous throm-
botic events and a small number of major bleedings in both arms.
Before the results of RESPECT CVT were made available, we 
conducted a multicenter prospective, observational study to 
evaluate the safety of NOACs compared to warfarin in patients 
with CVT. Data was collected from October 2016 to October 
2018. Nine centers in four countries Pakistan, Saudi Arabia, 
Egypt, and the United Arab Emirates participated in the study. All 
nine centers are tertiary care hospitals with full time neurologists 
and availability of diagnostic modalities for the diagnosis of CVT.
We included consecutive patients aged 18 years or more, who 
presented with clinical features of CVT, confirmed with venogra-
phy (either computed tomography [CT] or magnetic resonance 
[MR]). Those with traumatic or septic CVT were excluded.  Base-
line characteristics including demographics, Glasgow Coma 
Scale, clinical features, imaging findings, and anticoagulant at 
discharge were recorded. Choice of oral anticoagulation was left 
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Table 1. NOACs vs. warfarin for cerebral venous thrombosis (n=111)
Variable All patients (n=111) NOACs (n=45, 41%) Warfarin (n=66, 59%) P 
Age (yr) 39.3±14.9 36.5±14.7  41.3±14.8 0.10
Female sex 64 (57.7) 27 (60) 37 (56.1) 0.68
Predisposing factors
Pregnancy/puerperium 15 (23.1) 8 (28.6) 7 (18.9) 0.36
Hematological disorders 74 (66.7) 28 (62.2) 46 (69.7) 0.41
Malignancy 6 (5.4) 0 (0) 6 (10.5) 0.03
Systemic infections 36 (32.4) 15 (33.3) 21 (31.8) 0.86
Drugs/OCP 11 (9.9) 4 (9) 7 (11) 0.32
Other medical conditions 7 (6.3) 6 (13.3) 1 (1.5) 0.01
Clinical findings
Baseline GCS (available in 89 cases) 0.73
13–15 64 (71) 28 (74) 36 (70)
9–12 17 (19) 7 (18) 10 (20)
≤8 8 (10) 3 (8) 5 (10)
Seizures 37 (33.3) 14 (31) 23 (34.8) 0.68
Paresis 49 (44) 22 (48) 27 (52) 0.32
Aphasia 7 (6.3) 5 (11) 2 (3.0) 0.08
Headache 84 (75.7) 42 (93) 42 (63.6) <0.001
Papilledema 4 (3.6) 1 (2) 3 (4) 0.18
Imaging findings
Intracerebral hemorrhage 45 (40.5) 25 (55.6) 20 (30.3) 0.01
Venous infarction 54 (48.6) 25 (55.6) 29 (43.9) 0.22
Midline shift 10 (9.0) 4 (8.9) 6 (9.1) 0.97
Hydrocephalus 1 (0.9) 0 (0) 1 (1.5) 0.40
SSS thrombus 56 (50.5) 26 (57.8) 30 (45.5) 0.20
TS thrombus 60 (54.1) 30 (66.7) 30 (45.5) 0.02
Straight sinus/DCVT/cortical vein 28 (25.2) 11 (24.4) 17 (25.8) 0.87
Sigmoid sinus/jugular vein 62 (55.9) 29 (64.4) 33 (50) 0.13
Treatment
Heparin/LMWH 79 (71) 36 (80) 43 (65) 0.06
Surgery 12 (10.8) 5 (12.5) 7 (11.7) 0.90
Start of oral anticoagulation in days 6 (3–11) 7 (3–12) 5 (3–10)
mRS at discharge 111 45 66 0.52
0 23 (21) 11 (25) 12 (18)
1 29 (26) 11 (23) 18 (28)
2 28 (25) 12 (27) 16 (23)
3 15 (14) 4 (9) 11 (17)
4 10 (10) 5 (10) 5 (8)
5 2 (2) 1 (2) 1 (2)
6 4 (4) 1 (2) 3 (5)
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to the discretion of the treating physician. Recruited patients 
were followed up prospectively for outcomes assessment which 
was done by the treating physician in outpatient clinic setup. 
Treating physicians took verbal consent from the patients or 
their surrogates for contributing their data to the study. Ethics 
approval was taken from the Institutional Review Board of 
each participating center. Data was entered and analyzed on 
SPSS version 21 (IBM Co., Armonk, NY, USA).  
A total of 111 patients were included (45 were on NOACs 
and 66 on warfarin). Diagnosis was confirmed by magnetic 
resonance imaging (MRI)/magnetic resonance venography 
(MRV) in 96, CT venogram in 10 and both MRV and CT veno-
gram in five patients. Out of 45 patients on NOACs, 36 were 
given rivaroxaban and nine were given dabigatran. Warfarin 
was adjusted to achieve an international normalized ratio 
(INR) of 2 to 3. The mean age of the participants was 
39.3±14.9 years and 57% were females and the two groups 
were comparable (Table 1). Hematological disorders followed 
by systemic infections were the most common etiological 
factors for CVT in both the NOAC and warfarin groups. Ma-
lignancy was a more common predisposing factor in the war-
farin group, with six out of 66 patients suffering from the 
condition. No patient in the NOAC arm had malignancy. 
Whereas the two groups did not differ significantly in terms 
of clinical features, patients in the NOAC group presented more 
frequently with headache (93% vs. 63%) and were significant-
ly more likely than warfarin group to have intracerebral hem-
orrhage on initial imaging, reflecting the comfort of treating 
physician with NOACs. There were no other significant differ-
ences in the clinical and imaging features of the two groups. 
Patients in both groups were started on oral anticoagulation 
(warfarin with target INR 2 to 3; rivaroxaban 15 to 20 mg; 
dabigatrin 75 to 150 mg twice a day) within median of one 
week of diagnosis. At discharge as well as at 6 months follow-
up, the functional outcomes as measured by modified Rankin 
Scale, were not significantly different between the two groups. 
Four patients died during hospital stay, one in the NOAC arm 
and three in the warfarin arm. The hospital course was compli-
cated by extracranial hemorrhage in two patients, both of 
whom were in the warfarin group. Two additional patients 
were dead at 6 months follow-up, one in each group.
Follow-up ranged from minimum 6 to 13 months (median, 
8). All patients underwent neurological examination at follow-
up. Follow-up evaluation included history of headaches, sei-
zures, any signs of bleeding, side effects and compliance of 
medications, evaluation of modified Rankin Scale score and 
any imaging. At 6 months follow-up (95/107 discharged pa-
tients, 89%), clinical neurological worsening was reported in 
one patient (warfarin group), and no patient required switching 
from one to the other group. In addition, no patient required 
discontinuation of therapy by the physician. Only 12 patients 
(five in NOAC group, seven in warfarin group) had follow-up 
MRI/MRV (one patient for neurologic worsening, mostly for 
persistent headache and non-improvement) during 6 months 
follow-up. Of these, four in the NOAC arm and four in the war-
farin arm had complete and the rest had partial recanalization.
Six patients reported systemic bleeding at follow-up, two in 
the NOAC arm and four in the warfarin arm. As per Interna-
tional Society on Thrombosis and Haemostasis (ISTH) classifi-
cation, one patient had major, one non-major clinically rele-
vant, and four had minor hemorrhages. Only one patient in the 
NOAC arm required blood transfusion and a single patient in 
the warfarin group had intracranial hemorrhage that required 
intervention. No recurrent thrombotic events were seen in any 
of the patients.
This open label, comparative study reports on the largest co-
Table 1. Continued
Variable All patients (n=111) NOACs (n=45, 41%) Warfarin (n=66, 59%) P 
mRS at 6 months 95 39 56 0.30
0 37 (39) 17 (44) 20 (36)
1 23 (24) 8 (21) 15 (28)
2 19 (20) 10 (26) 9 (16)
3 9 (10) 2 (4) 7 (12)
4 4 (4) 1 (2) 3 (5)
5 3 (3) 1 (2) 2 (3)
6 2 (0.02) 1 (0.03) 1 (0.02)
Values are presented as mean±standard deviation, number (%), or median (interquartile range).
NOAC, new direct oral anticoagulant; OCP, oral contraceptive pill; GCS, Glasgow Coma Scale; SSS, superior sagittal sinus; TS, transverse sinus; DCVT, deep ce-
rebral vein thrombosis; LMWH, low molecular weight heparin; mRS, modified Rankin Scale.
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hort of CVT patients treated with new oral anticoagulants and 
shows that the use of NOACs (mainly rivaroxaban and dabiga-
tran) appear to be safe and may be as effective as warfarin in 
patients with CVT. Limitations of our study include non-ran-
domization, open label, lack of adequate radiological data at 
follow-up to assess recanalization and non-blinded and non-
adjudicated outcome assessments. Despite these, our study 
findings provide external validity for the RESPECT CVT results 
in a real-world setting and supports the growing trend of 
NOAC use for this potentially devastating condition. 
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